

Disease/Indication	Details
<p>Breast</p> <p>Adjuvant Supportive Care</p>	<p>Protocol: Alliance A221102 Sponsor: NCI</p> <p>Title: <i>Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01573442?term=a221102&rank=1</p>
<p>Breast</p> <p>Neo-Adjuvant HER2 + ER and/or PR +</p>	<p>Protocol: NSABP B-52 Sponsor: NCI</p> <p>Title: <i>A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neo-adjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02003209?term=nsabp+b52&rank=1</p>
<p>Breast</p> <p>Adjuvant BRAC 1/2 + HER2 – ER/PR < 1%</p>	<p>Protocol: NSABP B-55 Sponsor: NCI</p> <p>Title: <i>Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02032823?term=nsabp+b55&rank=1</p>
<p>Breast</p> <p>Adjuvant HER2 + NODE – NODE +</p>	<p>Protocol: BO28407 KAITLIN Sponsor: Hoffmann-La Roche</p> <p>Title: <i>A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracycline versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracycline as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer</i></p> <p>Locations: GCS Athens, Centerpointe, Cumming, Kennestone, Macon, & Stemmer; ACC Alpharetta & Cumming</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01966471</p>

Disease/Indication	Details
<p>Breast</p> <p>Advanced/Metastatic 1st/2nd/3rd line HER2 –</p>	<p>Protocol: INCB 18424-268 Sponsor: Incyte</p> <p>Title: <i>A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02120417</p>
<p>Breast</p> <p>Metastatic 1st/2nd/3rd line GpNMB + TNBC</p>	<p>Protocol: CDX-011-04 METRIC Sponsor: Celldex Therapeutics</p> <p>Title: <i>A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)</i></p> <p>Location: GCS Athens, Canton, Centerpointe, Cumming, Kennestone, Macon, & Stemmer</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01997333?term=cdx-011-04&rank=1</p>
<p>Breast</p> <p>Advanced/Metastatic HER2 – ER + Post AI Therapy</p> <p>OPENING MAY 20, 2015</p>	<p>Protocol: GO29058 SANDPIPER Sponsor: Hoffman-La Roche</p> <p>Title: <i>A Phase III, Double-Blind, Placebo Controlled, Randomized Study of Taselisib Plus Fulvestrant versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02340221?term=sandpiper&rank=1</p>
<p>Colon</p> <p>Metastatic 2nd line</p>	<p>Protocol: UNC LCCC1029 Sponsor: UNC Lineberger Comprehensive Cancer Center</p> <p>Title: <i>Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer</i></p> <p>Location: GCS Athens, Canton, Centerpointe, Cumming, Kennestone, Macon & Stemmer</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01298570?term=lccc1029&rank=1</p>

Disease/Indication	Details
<p>Colon</p> <p>Metastatic Relapsed/Refractory</p>	<p>Protocol: INCB 18424-267 Sponsor: Incyte</p> <p>Title: <i>A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer</i></p> <p>Location: GCS Athens, Centerpointe, Cumming, Kennestone, Macon & Stemmer; All ACC Research Offices</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02119676?term=incyte+267&rank=1</p>
<p>Leukemia</p> <p>CLL 1st line ≥ 65 years old</p>	<p>Protocol: Alliance A041202 Sponsor: NCI</p> <p>Title: <i>A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01886872?term=a041202&rank=1</p>
<p>Leukemia or Lymphoma</p> <p>CLL (with prior BTK) CLL (with prior PI3K) CLL (dose ranging) MCL Relapsed or Refractory</p>	<p>Protocol: GS-US-339-0102 Sponsor: Gilead</p> <p>Title: <i>A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies</i></p> <p>Location: GCS Athens, Canton, Centerpointe, Cumming, Kennestone, Macon & Stemmer</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/study/NCT01799889?term=gs-us-339-0102&rank=1</p>
<p>Lung</p> <p>Metastatic 1st line Adenocarcinoma</p> <p>CLOSING MAY 8, 2015</p>	<p>Protocol: ECOG E5508 Sponsor: NCI</p> <p>Title: <i>Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01107626?term=NCT00107626&rank=1</p>

Disease/Indication	Details
<p>Lung</p> <p>Adjuvant ALK + or EGFR +</p> <p><i>All eligible patients will be enrolled to protocol A151216 in order to have tumor genotyping performed per central lab.</i></p> <p><i>If patient is EGFR +, they may be enrolled to protocol A081105.</i></p> <p><i>If patient is ALK +, they may be enrolled to protocol E4512.</i></p>	<p>Protocol: A151216 Sponsor: NCI</p> <p>Title: <i>Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02194738?term=alchemist&rank=2</p>
	<p>Protocol: A081105 Sponsor: NCI</p> <p>Title: <i>Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02193282?term=alchemist&rank=3</p>
	<p>Protocol: E4512 Sponsor: NCI</p> <p>Title: <i>A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02201992?term=alchemist&rank=4</p>

Disease/Indication	Details
<p>Lung</p> <p>Metastatic Squamous Cell Carcinoma 2nd line</p>	<p>Protocol: SWOG S1400 Lung-MAP Sponsor: NCI</p> <p>Title: <i>S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer</i></p> <p>Location: Network</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02154490</p> <p>All eligible patients will be enrolled to protocol S1400 for biomarker profiling per Foundation Medicine. Based on those results, patients meeting detailed eligibility criteria will be assigned to one of the following Sub-Studies:</p> <p>Sub-study A: No known biomarker (MEDI4736 or Taxotere) Sub-study B: Target P13k (GDC-0032 or Taxotere) Sub-study C: Target CDK4/6 (Palbociclib or Taxotere) Sub-study D: Target FGFR (AZD4547 or Taxotere)</p>
<p>Lymphoma</p> <p>Hodgkin Lymphoma 1st line ≥ 60 years old</p>	<p>Protocol: Seattle Genetics Sponsor: Seattle Genetics</p> <p>Title: <i>A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above</i></p> <p>Location: GCS Athens, Canton, Centerpointe, Cumming, Kennestone, Macon & Stemmer</p> <p>Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01716806</p>
<p>Myeloma</p> <p>Multiple Myeloma 1st line</p>	<p>Protocol: ECOG E1A11 Sponsor: NCI</p> <p>Title: <i>Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01863550?term=e1a11&rank=1</p>

Disease/Indication	Details
<p>Melanoma</p> <p>Metastatic with Brain Mets 1st/2nd/3rd line V600 E, K, D, or R +</p>	<p>Protocol: GSK BR117277 COMBI-MB Sponsor: GlaxoSmithKline</p> <p>Title: <i>A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain</i></p> <p>Location: Network (Imaging MUST be performed at NSH ONLY)</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02039947?term=brf117277&rank=1</p>
<p>Melanoma</p> <p>Adjuvant Stage III or IV Completely resectable Identified before surgery Vaccine to follow SOC tx.</p>	<p>Protocol: Elios TLPLDC vaccine Sponsor: Cancer Insight, LLC</p> <p>Title: <i>A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence</i></p> <p>Location: GCS Centerpointe, Stemmer; ACC Tower, Alpharetta & Decatur; Melanoma Specialists of Georgia</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02301611?term=elios+tlpldc&rank=1</p>
<p>Melanoma</p> <p>Advanced Unresectable Stage III or IV Previously Treated</p> <p>OPENING MAY 27, 2015</p>	<p>Protocol: CDX011-05 Sponsor: Celldex Therapeutics</p> <p>Title: <i>A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, in Patients With Advanced Melanoma</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02302339?term=cdx011-05&rank=1</p>
<p>Prostate</p> <p>Metastatic 1st line Castration Resistant</p>	<p>Protocol: ALLIANCE A031201 Sponsor: NCI</p> <p>Title: <i>Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01949337?term=a031201&rank=1</p>

Disease/Indication	Details
<p>Pancreatic</p> <p>Adjuvant</p>	<p>Protocol: ABI-007-PANC-003 APACT Sponsor: Celgene</p> <p>Title: <i>A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma</i></p> <p>Location: GCS Athens, Centerpointe, Cumming, Kennestone, Macon & Stemmer; ACC Alpharetta & Decatur</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01964430?term=abi-007-panc-003&rank=1</p>
<p>Pancreatic</p> <p>Metastatic 1st line</p>	<p>Protocol: OMP-59R5-002 ALPINE Sponsor: OncoMed Pharmaceuticals</p> <p>Title: <i>A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer</i></p> <p>Location: GCS Athens, Centerpointe, Cumming, Kennestone, Macon & Stemmer</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01647828?term=omp-59r5&rank=1</p>
<p>Pancreatic</p> <p>Metastatic 2nd line</p>	<p>Protocol: INCB18424-363 JANUS-2 Sponsor: Incyte</p> <p>Title: <i>A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)</i></p> <p>Location: Network</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02119663?term=Janus+2&rank=1</p>
<p>Sarcoma</p> <p>Locally Advanced/Metastatic Unresectable 2nd line + Intermediate or High Grade Soft Tissue</p>	<p>Protocol: ALDOXORUBICIN-P3-ST5-01 Sponsor: CytRx</p> <p>Title: <i>A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy</i></p> <p>Location: GCS Centerpointe</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02049905?term=p3-sts-01&rank=1</p>

Disease/Indication	Details
<p>Sarcoma</p> <p>Adjuvant ≤ 12-weeks from surgery Uterine Leiomyosarcoma</p>	<p>Protocol: GOG0277 Sponsor: NCI</p> <p>Title: <i>A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma</i></p> <p>Location: GCS Centerpointe</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01533207?term=gog0277&rank=1</p>
<p>Phase I</p> <p>Breast</p>	<p>Protocol: MM-141-01-01-01 Sponsor: Merrimack</p> <p>Title: <i>A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors</i></p> <p>Location: GCS Centerpointe</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01733004?term=Merrimack+141&rank=2</p>
<p>Phase I</p> <p>Solid Tumor AML MDS Lymphoma MM</p>	<p>Protocol: INCB52793-101 Sponsor: Incyte</p> <p>Title: <i>A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies</i></p> <p>Location: GCS Centerpointe</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT02265510?term=incyte+101&rank=2</p>
<p>Phase I</p> <p>Solid Tumor Lymphoma</p>	<p>Protocol: ARQ-092-101 Sponsor: ArQule</p> <p>Title: <i>A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma</i></p> <p>Location: GCS Centerpointe</p> <p>Click for more information: https://clinicaltrials.gov/ct2/show/NCT01473095?term=arg+092-101&rank=1</p>